Latest News for: cd73

Edit

Antengene Announces Clinical Collaboration with Junshi Biosciences to Explore the Synergistic Potential of ATG-037 (Oral CD73 Inhibitor) In Combination with JS207 (PD-1/VEGF BsAb)

PR Newswire 25 Feb 2026
ATG-037, Antengene's orally administered small-molecule CD73 inhibitor, offers significant advantages over anti-CD73 monoclonal antibodies ... facilitate complete CD73 inhibition at the cellular level.
Edit

CD73 Inhibitors Pipeline Report 2025: an Up-to-date Competitor Evaluation in the Field of Antibodies, RNA ...

Nasdaq Globe Newswire 27 Nov 2025
CD73 inhibitors offer significant market opportunities in cancer treatment through novel immunotherapies ... CD73 inhibitors offer ...
  • 1

Article Search

tools
×
×
×
×